for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aclaris Therapeutics Inc

ACRS.OQ

Latest Trade

1.39USD

Change

-0.04(-2.46%)

Volume

25,895

Today's Range

1.39

 - 

1.42

52 Week Range

0.74

 - 

15.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.42
Open
1.39
Volume
25,895
3M AVG Volume
38.14
Today's High
1.42
Today's Low
1.39
52 Week High
15.95
52 Week Low
0.74
Shares Out (MIL)
41.37
Market Cap (MIL)
58.74
Forward P/E
-0.50
Dividend (Yield %)
--

Next Event

Aclaris Therapeutics, Inc. - Special Call

Latest Developments

More

Aclaris Therapeutics' Wart Therapy Meets Main And Secondary Goals In Phase 3 Trial

Aclaris Therapeutics Announces New Strategic Direction

Aclaris Therapeutics Reports Qtrly Loss Per Share $1.21

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

Industry

Biotechnology & Drugs

Contact Info

640 Lee Rd Ste 200

+1.484.3247933

https://www.aclaristx.com/

Executive Leadership

Neal Walker

President, Chief Executive Officer, Director

Frank Ruffo

Co-Founder, Chief Financial Officer

Stuart D. Shanler

Chief Scientific Officer

Kamil Ali-Jackson

Chief Legal Officer, Chief Compliance Officer, Secretary

David Gordon

Chief Medical Officer

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.250

2017

-2.440

2018

-4.030

2019(E)

-2.833
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.63
Price To Book (MRQ)
0.43
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
22.53
LT Debt To Equity (MRQ)
21.81
Return on Investment (TTM)
-89.11
Return on Equity (TTM)
-75.76

Latest News

BRIEF-Aclaris Therapeutics Q1 Loss Per Share $0.98

* ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

BRIEF-Aclaris Therapeutics Announces Availability Of Eskata In The U.S.

* ACLARIS THERAPEUTICS ANNOUNCES AVAILABILITY OF ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W)

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage:

BRIEF-Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met

* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS

BRIEF-Aclaris Therapeutics Q4 Revenue $1.0 Mln

* ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

BRIEF-Aclaris Therapeutics Issues U.S. Patent Covering JAK Inhibitor For Treating Hair Loss Disorders

* ACLARIS THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING A JAK INHIBITOR FOR TREATING HAIR LOSS DISORDERS Source text for Eikon: Further company coverage:

BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp

* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING

BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

Aclaris's drug to treat common skin growth gets FDA nod

Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

Aclaris's drug to treat common growth on skin gets FDA nod

Aclaris Therapeutics Inc said on Friday the U.S. Food and Drug Administration (FDA) had approved its topical drug to treat seborrheic keratoses, growths on the skin that are harmless but affect millions of Americans.

BRIEF-Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs

* ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS)

BRIEF-Aclaris Therapeutics wins patent in Japan for treating hair loss

* Aclaris Therapeutics announces the allowance of a U.S. patent application and issuance of a Japanese patent covering tofacitinib for treating hair loss disorders Source text for Eikon: Further company coverage:

BRIEF-Deerfield Mgmt reports 5.90 pct passive stake in Aclaris Therapeutics

* Deerfield Mgmt, L.P. reports 5.90 pct passive stake in Aclaris Therapeutics Inc as of Sept 29 - SEC filing Source text: (http://bit.ly/2wKeWrl) Further company coverage:

BRIEF-Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis

* Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis

BRIEF-Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders

* Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders Source text for Eikon: Further company coverage:

BRIEF-Vivo Ventures VII LLC reports 9.5 pct stake in Aclaris Therapeutics

* Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing

BRIEF-Aclaris announces pricing of public offering of common stock

* Aclaris announces pricing of public offering of common stock

BRIEF-Aclaris Therapeutics posts Q2 loss per share $‍0.56​

* Aclaris Therapeutics reports second quarter 2017 financial results

BRIEF-Aclaris Therapeutics has submitted a marketing authorization application with medicines product agency in Sweden

* Has submitted a marketing authorization application with medicines product agency in Sweden

BRIEF-Aclaris Therapeutics submits investigational new drug application for ATI-50002

* Aclaris Therapeutics submits investigational new drug application for ATI-50002 to treat Alopecia Areata

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up